These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31069135)

  • 21. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
    Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
    Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.
    Speranza MC; Passaro C; Ricklefs F; Kasai K; Klein SR; Nakashima H; Kaufmann JK; Ahmed AK; Nowicki MO; Obi P; Bronisz A; Aguilar-Cordova E; Aguilar LK; Guzik BW; Breakefield X; Weissleder R; Freeman GJ; Reardon DA; Wen PY; Chiocca EA; Lawler SE
    Neuro Oncol; 2018 Jan; 20(2):225-235. PubMed ID: 29016938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.
    Curry WT; Gorrepati R; Piesche M; Sasada T; Agarwalla P; Jones PS; Gerstner ER; Golby AJ; Batchelor TT; Wen PY; Mihm MC; Dranoff G
    Clin Cancer Res; 2016 Jun; 22(12):2885-96. PubMed ID: 26873960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.
    Renner DN; Jin F; Litterman AJ; Balgeman AJ; Hanson LM; Gamez JD; Chae M; Carlson BL; Sarkaria JN; Parney IF; Ohlfest JR; Pirko I; Pavelko KD; Johnson AJ
    PLoS One; 2015; 10(5):e0125565. PubMed ID: 25933216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy combined with anti-CEACAM1 immunotherapy to induce survival advantage in glioma.
    Li J; Chen Y; Fan Y; Wang H; Mu W; Liu X
    Discov Oncol; 2023 Mar; 14(1):32. PubMed ID: 36928507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
    Dai B; Qi N; Li J; Zhang G
    Biochem Biophys Res Commun; 2018 Jul; 501(4):871-876. PubMed ID: 29758196
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained localized delivery of immunotherapy to lymph nodes reverses immunosuppression and increases long-term survival in murine glioblastoma.
    Choi J; Pant A; Medikonda R; Kim YH; Routkevitch D; Saleh L; Tong L; Chan HY; Nedrow J; Jackson C; Jackson C; Lim M
    Oncoimmunology; 2021; 10(1):1940673. PubMed ID: 34290904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Zika virus-based immunotherapy enhances long-term survival of rodents with brain tumors through upregulation of memory T-cells.
    Crane AT; Chrostek MR; Krishna VD; Shiao M; Toman NG; Pearce CM; Tran SK; Sipe CJ; Guo W; Voth JP; Vaid S; Xie H; Lu WC; Swanson W; Grande AW; Schleiss MR; Bierle CJ; Cheeran MC; Low WC
    PLoS One; 2020; 15(10):e0232858. PubMed ID: 33002018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
    Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reprogramming macrophage by targeting VEGF and CD40 potentiates OX40 immunotherapy.
    Liu Y; Ma Q; Yang K; Zhang D; Li F; Chen J; Zhou F; Wang H; Li N; Wang Y; Cao Y; Zhang C; Li X; Zhang H; Wang W; Li Y
    Biochem Biophys Res Commun; 2024 Feb; 698():149546. PubMed ID: 38266314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cure of established GL261 mouse gliomas after combined immunotherapy with GM-CSF and IFNgamma is mediated by both CD8+ and CD4+ T-cells.
    Smith KE; Fritzell S; Badn W; Eberstål S; Janelidze S; Visse E; Darabi A; Siesjö P
    Int J Cancer; 2009 Feb; 124(3):630-7. PubMed ID: 18972433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
    Mathios D; Park CK; Marcus WD; Alter S; Rhode PR; Jeng EK; Wong HC; Pardoll DM; Lim M
    Int J Cancer; 2016 Jan; 138(1):187-94. PubMed ID: 26174883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells.
    Herrlinger U; Kramm CM; Johnston KM; Louis DN; Finkelstein D; Reznikoff G; Dranoff G; Breakefield XO; Yu JS
    Cancer Gene Ther; 1997; 4(6):345-52. PubMed ID: 9408604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice.
    Bu N; Wu H; Zhang G; Zhan S; Zhang R; Sun H; Du Y; Yao L; Wang H
    J Mol Neurosci; 2015 Jul; 56(3):631-43. PubMed ID: 25680514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences of tumor-recruiting myeloid cells in murine squamous cell carcinoma influence the efficacy of immunotherapy combined with a TLR7 agonist and PD-L1 blockade.
    Tachinami H; Nishii N; Xia Y; Kashima Y; Ohno T; Nagai S; Li L; Lau W; Tomihara K; Noguchi M; Azuma M
    Oral Oncol; 2019 Apr; 91():21-28. PubMed ID: 30926058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors.
    Eberstål S; Sandén E; Fritzell S; Darabi A; Visse E; Siesjö P
    Int J Cancer; 2014 Jun; 134(11):2748-53. PubMed ID: 24243648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.
    Chonan M; Saito R; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Watanabe M; Kikuchi T; Ishii N; Tominaga T
    Neuro Oncol; 2015 Nov; 17(11):1453-62. PubMed ID: 26008605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.